CHATSWORTH, Calif., April 10, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of high-value personalized diagnostics testing, today announced that it has issued inducement awards to four new non-executive employees.
The awards were made on April 10, 2012 under IRIS International's 2011 Inducement Incentive Plan, which provides for the granting of equity awards to new employees of IRIS International and its subsidiaries as an inducement to join the company. The inducement awards consist of options to purchase up to 2,252 shares of IRIS common stock and restricted stock units for 1,020 shares of IRIS common stock. The options have a seven year term and an exercise price of $12.53, which was the closing price of a share of IRIS common stock on the date of grant. The awards vest over four years, with the restricted stock units vesting 25% on a date which is 13 months following the employee's start date and the balance vesting thereafter in 12 equal quarterly installments, and the options vesting 25% on the first anniversary of the employee's start date and the balance vesting thereafter in 12 equal quarterly installments.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,200 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and body fluids. In addition, the Company's personalized medicine group has a high complexity CLIA-certified laboratory supporting the development and commercialization of the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay technology platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.